Asceneuron S.A.

https://www.asceneuron.com

LinkedIn: https://www.linkedin.com/company/asceneuron-sa

Asceneuron is an emerging, clinical stage biotech company excelling in the development of orally bioavailable therapeutics for debilitating neurodegenerative disorders with high unmet medical needs such as orphan tauopathies, Alzheimer’s and Parkinson’s diseases. The lead product, an O-GlcNAcase inhibitor that in preclinical studies has been demonstrated to modulate tau pathology, has received regulatory approval to start the first human clinical testing. The O-GlcNAcase inhibitor is being developed for the orphan tauopathy progressive supranuclear palsy (PSP). Asceneuron is a privately held company financed by a strong syndicate of investors consisting of Sofinnova Partners, Merck Ventures, SR One, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) and Kurma Partners. *

	Start	2012-10-02 splitoff
	Predecessor	Merck Serono (division of Merck KGaA)
	Industry	Alzheimer drug
	Industry 2	ASN90 (formerly ASN120290 + ASN-561, Ferrer/Asceneuron)
	Person	Angehrn Pavik, Barbara (Asceneuron 202310– CEO before Vifor + Stepstone Pharma + Exelixis + Onyx + Amgen)
	Person 2	Beher, Dirk (FundaMental Pharma 202404– CEO before Asceneuron + MSD UK + Amgen + Merck Serono)

	Region	Lausanne VD
	Country	Switzerland
	City	1015 Lausanne VD
		Address record changed: 2024-07-17

Basic data	Employees	C: 51 to 100 (2022-01-01)

		* Document for »About Section«:

		Record changed: 2024-07-17